Ramosetron
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Ramosetron: From Its Marketed Use to Insomnia
One-Sentence Summary
Ramosetron is a selective 5-HT3 receptor antagonist that is marketed in India as tablets and an injection. The TxGNN model predicts it may be effective for insomnia, with a second prediction for migraine disorder. Currently no clinical trials and no publications support either prediction, so this is a model-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed in the Indian license records compiled for this report |
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 0.9973 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (3 of 3) – CDSCO approval status is not included in this data |
| Number of Listed Products | 3 (valid: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Ramosetron is known to be a selective 5-HT3 receptor antagonist, a class used for nausea and vomiting and for diarrhoea-predominant irritable bowel syndrome. Mechanistically, it may be applicable to insomnia, but this has not been demonstrated.
A plausible link is serotonergic signalling. 5-HT3 receptors are found in brain regions involved in sleep-wake regulation, and gut-brain axis signalling may influence sleep quality. However, preclinical data on 5-HT3 antagonism and sleep architecture are mixed, and there is no direct evidence for ramosetron.
The second-ranked prediction, migraine disorder (score 0.9906), rests on similar reasoning. Serotonin is involved in trigeminovascular activation, and 5-HT3 antagonists already relieve migraine-associated nausea and vomiting. Other drugs in the class have shown limited or inconsistent effects on migraine pain itself. Like insomnia, this prediction is also at evidence level L5 with a Hold recommendation.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 150936 | Nozia Tablet | Strip of 2 tablets | Not specified |
| 107757 | Ibset Tablet | Strip of 15 tablets | Not specified |
| 151215 | Nozia Injection | Vial of 2 ml injection | Not specified |
All three are single-ingredient products from Zydus Cadila and are currently valid.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The insomnia prediction has a high model score but no clinical trials or publications behind it, so it stays at evidence level L5. The migraine prediction is in the same position. Package insert safety data is also missing, which blocks safety screening.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Indian regulator’s product information
- Confirmed approved indications for the three registered products
- Mechanism of action data for ramosetron
- Literature and trial searches specific to ramosetron in insomnia (and migraine)
- Assessment of whether the available routes (oral, injectable) suit the intended use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.